What's Happening?
A multicenter clinical study published in JAMA Surgery has confirmed the diagnostic performance of Cizzle Bio's DEX-G2 blood test for early detection of gastric cancer. The study, conducted at cancer centers in Japan and South Korea, evaluated microRNAs from exosomes and serum, demonstrating high accuracy in detecting early-stage gastric cancer. The test achieved a sensitivity of 95% and an area under the curve of 96.8%, underscoring its potential as a minimally invasive screening tool. The study was led by Ajay Goel, Ph.D., who developed the Destinex assay, the basis for the DEX-G2 test.
AD
Why It's Important?
Gastric cancer is a leading cause of cancer-related deaths globally, often diagnosed at advanced stages. The DEX-G2 test offers a less invasive, cost-effective alternative to endoscopic screening, which is impractical in low-incidence regions. By enabling earlier detection, the test could significantly improve patient outcomes and reduce mortality rates. Cizzle Bio plans to commercialize the test in the U.S. and globally, potentially transforming gastric cancer diagnostics and treatment.
What's Next?
Cizzle Bio is advancing the DEX-G2 test for commercial deployment in CLIA-certified labs, aiming to support clinicians in early gastric cancer detection. The company holds exclusive licensing rights and is pursuing commercialization in markets where late diagnosis is common. This initiative could lead to widespread adoption of the test, improving access to early diagnostic tools and interventions.
